Biomarker analysis firm Quanterix said it plans to make a public offering of $75 million shares of its common stock.
The company will grant underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, it said; all shares will be sold by Quanterix.
J.P. Morgan Securities and SVB Leerink are joint book-running managers for the offering, and Canaccord Genuity is co-manager, according to the firm.
